Skip to main content
. 2020 Nov 26;10:20628. doi: 10.1038/s41598-020-77456-6

Table 1.

Number of patients and HPE findings in each study group.

Group n (%) Benign n (%) Malignant n (%)
Diagnostic 243/390 (62.3) 89/243 (36.6) 154/243 (63.4)
Opportunistic screening 110/390 (28.2) 91/110 (82.7) 19/100 (17.3)
Targeted screening 37/390 (9.5) 28/37 (75.7) 9/37 (24.3)